Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : Glenmark Pharmaceuticals
Deal Size : $37.9 million
Deal Type : Divestment
JB Pharma To Acquire The Entire Razel (rousvastatin) Franchise From Glenmark Pharmaceuticals Ltd
Details : Razel (rosuvastatin) is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.
Brand Name : Razel
Molecule Type : Small molecule
Upfront Cash : $37.9 million
December 14, 2022
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : Glenmark Pharmaceuticals
Deal Size : $37.9 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?